Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
Go back to Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 124.93 -1.82 (1.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.75 | 52 Week High | $118.49 | |||
| Open | $124.11 | 52 Week Low | $55.00 | |||
| Day High | $125.70 | P/E | N/A | |||
| Day Low | $122.22 | EPS | $-0.56 | |||
| Volume | 271,853 | |||||
